Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 283

Sort by

Sort Order Select

Journal Articles

Cost Comparison of Ruxolitinib and Momelotinib in Patients with Myelofibrosis and Anemia

Aaron T. Gerds, Jingbo Yu, Charles Tao, Rashad Carlton, Evan M. Braunstein, Ruben A. Mesa

Blood (2024) 144 (Supplement 1): 6655.

https://doi.org/10.1182/blood-2024-193686

Published: 2024

Journal Articles

A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

John O. Mascarenhas, Uma Borate, Prithviraj Bose, John C. Byrd, Jacqueline S. Garcia, Michael R. Grunwald, Gabriela S. Hobbs, Ronald Hoffman, Andrew T. Kuykendall, Ruben A. Mesa, Stephen Oh, Raajit Rampal, Abdulraheem Yacoub, David P. Steensma

Blood (2024) 144 (Supplement 1): 3147.1.

https://doi.org/10.1182/blood-2024-193905

Published: 2024

Journal Articles

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Ghaith Abu-Zeinah, Albert Qin, Harinder Gill, Norio Komatsu, John O. Mascarenhas, Weichung Joe Shih, Oleh Zagrijtschuk, Toshiaki Sato, Kazuya Shimoda, Richard T. Silver, Ruben A. Mesa

Blood (2024) 144 (Supplement 1): 3191.1.

https://doi.org/10.1182/blood-2024-200319

Published: 2024

Journal Articles

Findings from a Longitudinal Series of Continuing Education and Quality Improvement Programs in Myelofibrosis

Joseph Kim, Ruben A. Mesa, Linda Gracie-King, Marc David Viens, Victor Ocana, Stephanie Wenick

Blood (2024) 144 (Supplement 1): 3673.

https://doi.org/10.1182/blood-2024-199378

Published: 2024

Journal Articles

Infusion Immediate Care: Improving Hematology/Oncology Practice Quality through Expanded and Timely Access to Infusion Care

Melissa Barnes, Christina Villa, Brenda Crump, Donna Field, Seungjean Chai, Ruben A. Mesa, Payal Desai, Sridhar Pal, Jennifer Gray, Brittany Knick Ragon

Blood (2024) 144 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2024-200106

Published: 2024

Journal Articles

Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib

Stephen T. Oh, Jamile Shammo, Vikas Gupta, Mary Frances McMullin, Prithviraj Bose, Ruben A. Mesa, Alessandro Lucchesi, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John Mascarenhas, Francisca Ferrer Marin

Blood (2023) 142 (Supplement 1): 4566.

https://doi.org/10.1182/blood-2023-178753

Published: 2023

Journal Articles

Anemia and Transfusion Dependency Are Important Prognostic Factors for Overall Survival in Patients with Myelofibrosis: Results of a Real-World Analysis of Medicare Patients

Aaron T. Gerds, Ruben A. Mesa, Joseph Tkacz, Laura Moore-Schiltz, Jill Schinkel, Kelesitse Phiri, Tom Liu, Boris Gorsh

Blood (2023) 142 (Supplement 1): 6418.

https://doi.org/10.1182/blood-2023-178012

Published: 2023

Journal Articles

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Ruben A. Mesa, Andrew C. Perkins, Yeow Tee Goh, Maria Laura Fox, Donal P McLornan, Jeanne Palmer, Lynda Foltz, Alessandro Maria Vannucchi, Steffen Koschmieder, Francesco Passamonti, Sung-Eun Lee, Jun Kawashima, Bryan Strouse, Francisco Gonzalez Carreras, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 3182.

https://doi.org/10.1182/blood-2023-177774

Published: 2023

Journal Articles

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Vikas Gupta, Claire N Harrison, Boris Gorsh, Bharat Patel, Zhaohui Wang, Molly Purser, Catherine Ellis, Bryan Strouse, Dwaipayan Patnaik, Jun Kawashima, Ruben A. Mesa

Blood (2023) 142 (Supplement 1): 3188.

https://doi.org/10.1182/blood-2023-178772

Published: 2023

Journal Articles

Progression to Myelofibrosis in Patients with Essential Thrombocythemia: A Real-World Analysis from the Prospective MOST Study

Abdulraheem Yacoub, Roger M. Lyons, Evan M. Braunstein, JE Hamer-Maansson, Tricia Kalafut, Ruben A. Mesa

Blood (2023) 142 (Supplement 1): 2433.

https://doi.org/10.1182/blood-2023-180240

Published: 2023

Journal Articles

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Ruben A. Mesa, Moshe Talpaz, Flora Mazerolle, Boris Gorsh, Manal M'Hari, Antoine Regnault, Catherine Ellis, Zhaohui Wang, Molly Purser, Tom Liu, Bryan Strouse, Dwaipayan Patnaik

Blood (2023) 142 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2023-177784

Published: 2023

Journal Articles

Clinical Practice Gaps in Managing Patients with Myelofibrosis: Comparison of Healthcare Professional and Expert Treatment Choices Provided to an Online Decision Support Tool

Ryan P. Topping, Prithviraj Bose, John Mascarenhas, Raajit K. Rampal, Brady L. Stein, Timothy A. Quill, Ruben A. Mesa

Blood (2023) 142 (Supplement 1): 7291.

https://doi.org/10.1182/blood-2023-174268

Published: 2023

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

Journal Articles

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Blood (2021) 138 (Supplement 1): 2568.

https://doi.org/10.1182/blood-2021-152267

Published: 2021

Journal Articles

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Jean-Jacques Kiladjian, Ayalew Tefferi, Francesco Passamonti, Alessandro Vannucchi, Moshe Talpaz, Francisco Cervantes, Claire N. Harrison, Ruben A. Mesa, John Mascarenhas, Nicolaas Schaap, Srdan Verstovsek, Timothy Devos, Shelonitda Rose, Jun Zhang, Oumar Sy, Animesh Pardanani

Blood (2021) 138 (Supplement 1): 2576.

https://doi.org/10.1182/blood-2021-147618

Published: 2021

Journal Articles

Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

Ruben A. Mesa, Norio Komatsu, Harinder Gill, Jie Jin, Sung-Eun Lee, Hsin-An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 1491.

https://doi.org/10.1182/blood-2021-147417

Published: 2021

Journal Articles

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Chandan Saha, Carolyn Mead-Harvey, Adam J. Mead, Rebecca H. Boucher, Sonia Fox, Isaak Ailts, Christina Yap, Aimee E Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Ruben A. Mesa, Robyn Scherber, Mary Frances McMullin, Holly L. Geyer, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2021-151568

Published: 2021

Journal Articles

Does Early Intervention in Myelofibrosis Impact Outcomes? a Pooled Analysis of the Comfort I and II Studies

Srdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Ruben A. Mesa, Robyn Scherber, J.E. Hamer-Maansson, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1505.

https://doi.org/10.1182/blood-2021-150894

Published: 2021

Journal Articles

Advancing Personalized Care for Patients with Myeloproliferative Neoplasms (MPNs): Findings from a Phase 2 Scale-up Quality Initiative across Two Large U.S. Oncology Systems

Srdan Verstovsek, Ruben A. Mesa, Shelby Sullivan, Jeffrey D Carter, Cherilyn Heggen

Blood (2021) 138 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2021-148477

Published: 2021

NARROW

Cost Comparison of Ruxolitinib and Momelotinib in Patients with Myelofibrosis and Anemia

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Findings from a Longitudinal Series of Continuing Education and Quality Improvement Programs in Myelofibrosis

Infusion Immediate Care: Improving Hematology/Oncology Practice Quality through Expanded and Timely Access to Infusion Care

Retrospective Analysis of the Relationship between Transfusion Independence and Bone Marrow Fibrosis Reduction in Patients with Myelofibrosis Treated with Pacritinib Versus Ruxolitinib

Anemia and Transfusion Dependency Are Important Prognostic Factors for Overall Survival in Patients with Myelofibrosis: Results of a Real-World Analysis of Medicare Patients

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

Progression to Myelofibrosis in Patients with Essential Thrombocythemia: A Real-World Analysis from the Prospective MOST Study

Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials

Clinical Practice Gaps in Managing Patients with Myelofibrosis: Comparison of Healthcare Professional and Expert Treatment Choices Provided to an Online Decision Support Tool

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Does Early Intervention in Myelofibrosis Impact Outcomes? a Pooled Analysis of the Comfort I and II Studies

Advancing Personalized Care for Patients with Myeloproliferative Neoplasms (MPNs): Findings from a Phase 2 Scale-up Quality Initiative across Two Large U.S. Oncology Systems

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only